JP2005511748A - Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート - Google Patents

Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート Download PDF

Info

Publication number
JP2005511748A
JP2005511748A JP2003551152A JP2003551152A JP2005511748A JP 2005511748 A JP2005511748 A JP 2005511748A JP 2003551152 A JP2003551152 A JP 2003551152A JP 2003551152 A JP2003551152 A JP 2003551152A JP 2005511748 A JP2005511748 A JP 2005511748A
Authority
JP
Japan
Prior art keywords
ppm
nmr
cdcl
yield
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003551152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511748A5 (enExample
Inventor
ジャン−ルイス モンテロ
イブラヒム ツェガニ
シャンタル メニュー
ヴァレリー ガロア
Original Assignee
ラボラトワール マヨリー スピンドレ
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク
ユニヴェルジット モンペリエ ２
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトワール マヨリー スピンドレ, サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク, ユニヴェルジット モンペリエ ２ filed Critical ラボラトワール マヨリー スピンドレ
Publication of JP2005511748A publication Critical patent/JP2005511748A/ja
Publication of JP2005511748A5 publication Critical patent/JP2005511748A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3895—Pyrophosphonic acids; phosphonic acid anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
JP2003551152A 2001-12-11 2002-12-05 Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート Pending JP2005511748A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0115971A FR2833266B1 (fr) 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
PCT/FR2002/004190 WO2003050128A1 (fr) 2001-12-11 2002-12-05 PHOSPHONATES UTILES COMME MODULATEURS DE L'ACTIVITE DES LYMPHOCYTES t-GAMMA-9-DELTA-2

Publications (2)

Publication Number Publication Date
JP2005511748A true JP2005511748A (ja) 2005-04-28
JP2005511748A5 JP2005511748A5 (enExample) 2010-04-08

Family

ID=8870319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551152A Pending JP2005511748A (ja) 2001-12-11 2002-12-05 Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート

Country Status (6)

Country Link
US (2) US20060241087A1 (enExample)
EP (1) EP1453840A1 (enExample)
JP (1) JP2005511748A (enExample)
AU (1) AU2002366577A1 (enExample)
FR (1) FR2833266B1 (enExample)
WO (1) WO2003050128A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020002085A (ja) * 2018-06-29 2020-01-09 国立研究開発法人産業技術総合研究所 有機リン化合物
JP2021505562A (ja) * 2017-12-11 2021-02-18 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ ホスホノ−ホスフェート及びアニオン性基含有ポリマーを含む口腔ケア組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
BRPI0417088A (pt) * 2003-12-02 2007-03-13 Innate Pharma ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20070218086A1 (en) * 2004-04-26 2007-09-20 Innate Pharma, S.A. Adjuvant Composition and Methods for Its Use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
WO2007039635A2 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CN111432891B (zh) 2017-12-11 2024-01-02 宝洁公司 含膦酰基-磷酸根基团和阴离子基团的聚合物
EP3723701B1 (en) 2017-12-11 2025-08-06 The Procter & Gamble Company Method of making phosphono-phosphate containing compounds
WO2019118419A1 (en) * 2017-12-11 2019-06-20 The Procter & Gamble Company Compositions comprising multi-valent cations and phosphono-phosphate containing polymers
WO2019118416A1 (en) * 2017-12-11 2019-06-20 The Procter & Gamble Company Phosphono-phosphate containing compounds and polymers
MX390467B (es) 2017-12-11 2025-03-20 Procter & Gamble Composiciones para el cuidado bucal que comprenden polimeros que contienen grupos fosfonato y anionicos
EP3856206A1 (en) 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2034481A1 (en) * 1969-01-23 1970-12-11 Merck & Co Inc (2,3-epoxypropyl)-phosphonic acid derivs with - antibacterial activity
JPS5334727A (en) * 1976-09-06 1978-03-31 Anvar Preparation of 1*22epoxypropylphosphonic acid derivative
EP0534546A1 (en) * 1991-09-27 1993-03-31 Merck & Co. Inc. Farnesyl pyrophosphate analogs
JPH08509470A (ja) * 1993-02-23 1996-10-08 メレルダウファーマスーティカルズ インコーポレイテッド 抗がん剤としてのファルネシル：タンパク質トランスフェラーゼ阻害剤
US5827838A (en) * 1992-10-06 1998-10-27 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno & Rijksuniversteit Te Leiden Method for the treatment of diseases related with protein isoprenylation
JP2000500758A (ja) * 1995-11-23 2000-01-25 ラボラトリ バルダッチ エス．ピー．エー． 新規なゲラニルゲラニル誘導体、その製造方法および関連する薬剤組成物
WO2000012519A1 (fr) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphoepoxydes, procede de fabrication et applications
WO2000012516A1 (fr) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphohalohydrines, procede de fabrication et applications
WO2000043403A1 (en) * 1999-01-21 2000-07-27 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
WO2000059916A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale Composes inhibitant selectivement les lymphocytes t gamma 9 delta 2
JP2005508305A (ja) * 2001-07-20 2005-03-31 バイオエージェンシー・アーゲー ガンマ／デルタｔ細胞を活性化するための有機リン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US5177239A (en) * 1989-07-18 1993-01-05 E. R. Squibb & Sons, Inc. Method for preparing a phosphonic acid ester
WO1994019357A1 (en) * 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
EP1169996A1 (de) * 2000-07-06 2002-01-09 Ernst Mühlbauer Kg Phosphonsäuren enthaltendes Dentalmaterial
DE10201458A1 (de) 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2034481A1 (en) * 1969-01-23 1970-12-11 Merck & Co Inc (2,3-epoxypropyl)-phosphonic acid derivs with - antibacterial activity
JPS5334727A (en) * 1976-09-06 1978-03-31 Anvar Preparation of 1*22epoxypropylphosphonic acid derivative
EP0534546A1 (en) * 1991-09-27 1993-03-31 Merck & Co. Inc. Farnesyl pyrophosphate analogs
US5827838A (en) * 1992-10-06 1998-10-27 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno & Rijksuniversteit Te Leiden Method for the treatment of diseases related with protein isoprenylation
JPH08509470A (ja) * 1993-02-23 1996-10-08 メレルダウファーマスーティカルズ インコーポレイテッド 抗がん剤としてのファルネシル：タンパク質トランスフェラーゼ阻害剤
JP2000500758A (ja) * 1995-11-23 2000-01-25 ラボラトリ バルダッチ エス．ピー．エー． 新規なゲラニルゲラニル誘導体、その製造方法および関連する薬剤組成物
WO2000012519A1 (fr) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphoepoxydes, procede de fabrication et applications
WO2000012516A1 (fr) * 1998-09-01 2000-03-09 Institut National De La Sante Et De La Recherche Medicale Phosphohalohydrines, procede de fabrication et applications
WO2000043403A1 (en) * 1999-01-21 2000-07-27 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
WO2000059916A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale Composes inhibitant selectivement les lymphocytes t gamma 9 delta 2
JP2005508305A (ja) * 2001-07-20 2005-03-31 バイオエージェンシー・アーゲー ガンマ／デルタｔ細胞を活性化するための有機リン化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505562A (ja) * 2017-12-11 2021-02-18 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ ホスホノ−ホスフェート及びアニオン性基含有ポリマーを含む口腔ケア組成物
JP2020002085A (ja) * 2018-06-29 2020-01-09 国立研究開発法人産業技術総合研究所 有機リン化合物
JP7065513B2 (ja) 2018-06-29 2022-05-12 国立研究開発法人産業技術総合研究所 有機リン化合物

Also Published As

Publication number Publication date
US8017596B2 (en) 2011-09-13
EP1453840A1 (fr) 2004-09-08
US20100204184A1 (en) 2010-08-12
WO2003050128A1 (fr) 2003-06-19
US20060241087A1 (en) 2006-10-26
FR2833266B1 (fr) 2004-10-22
AU2002366577A1 (en) 2003-06-23
FR2833266A1 (fr) 2003-06-13

Similar Documents

Publication Publication Date Title
US8017596B2 (en) Phosphonates useful as modulators of T-γ-9-δ-2 activity
Puech et al. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process
KR102057751B1 (ko) 테노포비르 전구약물 및 그의 약학적 용도
CA2977839C (en) Tc-ptp inhibitors as apc activators for immunotherapy
KR102733555B1 (ko) 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법
AU2025234182A1 (en) Therapeutic compounds for hiv virus infection
KR100906018B1 (ko) 감마/델타 ｔ세포 활성화를 위한 유기-인 화합물
EP2331525A2 (en) Halofuginone analogs for inhibition of trna synthetases and uses thereof
EA014685B1 (ru) Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
JP4603163B2 (ja) ホスホハロヒドリン、これらの製造方法、及び使用
TW201228665A (en) Antiviral compounds
AU2005330489A1 (en) Nucleoside phosphonate conjugates as anti HIV agents
BRPI0713961A2 (pt) compostos fosfinatos antivirais
KR20180044425A (ko) 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제
JP2024116239A (ja) ホスホ抗原プロドラッグ化合物
CN109666637B (zh) Vγ9Vδ2 T及其激动剂在治疗肝纤维化、肝硬化和肝癌中的应用
JPH01501864A (ja) 抗ウイルス剤
NZ542343A (en) Immunomodulator phosphonate conjugates
US6624151B1 (en) Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes
KR20240049311A (ko) 인지질 화합물 및 이의 제조 및 사용 방법
EP1991554B1 (en) Thiopyrophosphate organic compounds, method for preparing thereof and compositions containing them
AU2013200563C1 (en) Antiviral phosphinate compounds
JP2021528465A (ja) 代謝安定性プロドラッグ
HK1161718A (en) Halofuginone analogs for inhibition of trna synthetases and uses thereof
AU2004233992A1 (en) Immunomodulator phosphonate conjugates

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100514

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101207